of at least 30 mL/min/1.73m 2 to 3 different doses of felzartamab or placebo on top of background ...

Mineralys Therapeutics, Inc. (MLYS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today.

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

New research finds that taking a daily vitamin D supplement may help lower blood pressure, especially for older adults with ...

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research Report). The ...

Mineralys Therapeutics, Inc. ( (MLYS) ) has released its Q3 earnings. Here is a breakdown of the information Mineralys ...

Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering ...

The aldosterone-renin ratio (ARR) has gained popularity as a screening test for primary hyperaldosteronism, a probably underdiagnosed cause of hypertension. However, studies have yielded varying ...

For patients with primary hyperaldosteronism, AVS is sometimes essential in identifying whether excess aldosterone production originates from one or both adrenal glands. This precision allows doctors ...

The relationship between pneumonia and cardiovascular disease goes both ways: Pneumonia can increase the risk of heart ...

Drawing inferences from observational data with possible confounding Heart failure is increasing in prevalence and is a major cause of morbidity and mortality worldwide,1 with prevalence ranging from ...

Meanwhile, some people might notice they can no longer tolerate the cold—which is one sign of hypothyroidism, or an underactive thyroid. The condition slows metabolism and triggers a drop in body ...